NEW YORK (GenomeWeb News) – Opko Health said today that it has expanded a collaboration with Bristol-Myers Squibb to include biomarker discovery for pharmacogenomic tests for use in treating Alzheimer's disease.

The Miami-based diagnostics and biopharmaceutical firm said that the deal builds on an earlier partnership aimed at studying the utility of Opko's Alzheimer's diagnostic technologies to now include efforts to identify biomarkers that can predict blood response in several therapeutic areas.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.